P53 mutations in phenacetin-associated human urothelial carcinomas

Carcinogenesis

Volumn 14, Issue 10, 1993, Pages 2119-2122

  Petersen, Iver ^a   Ohgaki, Hiroko ^a   Ludeke, Barbara I ^a   Kleihues, Paul ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CYTOSINE; MUTANT PROTEIN; PHENACETIN; PROMUTAGEN; PROTEIN P53; SINGLE STRANDED DNA;

ADULT; AGED; ANALGESIC NEPHROPATHY; ARTICLE; BLADDER TUMOR; CLINICAL ARTICLE; CODON; CONFORMATIONAL TRANSITION; DIAGNOSTIC VALUE; DNA DAMAGE; DNA POLYMORPHISM; DNA SEQUENCE; DRUG ABUSE; EXON; FEMALE; FRAMESHIFT MUTATION; GENE MUTATION; HUMAN; KIDNEY PELVIS TUMOR; LUNG METASTASIS; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; URETER TUMOR; URINARY TRACT; UROGENITAL TRACT TUMOR;

AGED; BASE SEQUENCE; BLADDER NEOPLASMS; CODON; EXONS; FEMALE; GENES, P53; HUMAN; KIDNEY NEOPLASMS; KIDNEY PELVIS; MALE; MIDDLE AGE; MOLECULAR SEQUENCE DATA; PHENACETIN; POINT MUTATION; URETERAL NEOPLASMS;

EID: 0027454322     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/14.10.2119     Document Type: Article

References (44)

1. Mihatsch, M.J., Torhors, LJ., Steinmann, E., Hofer, H., Stickelberger, M., Biandri, L., Bemeis, K. and Zollinger, H.U. (1979) The morphologic diagnosis of analgesic (phenacetin) abuse. PathoL Res. Pract., 164, 68-79.
2. Huhengreii, N., Lagergren, C. and ljungquist, A. (1965) Carcinoma of the renal pelvis in renal papillary necrosis. Acta Chir. Scand., 130, 314-320.
3. Johansson, S., Angervall, L., Bengtsson, U. and Wahlquist, L. (1974) Uroepithelial tumors of the renal pelvis associated with abuse of phenacetin containing analgesics. Cancer, 33, 743-753.
4. Mihalsch, M J. and Kniisli, C. (1982) Phenacetin abuse and malignant tumors. Klin. Wochenschr., 60, 1339-1349.
5. Steffens J. and Nagel, R. (1988) Tumours of the renal pelvis and ureter. Br. J. Urol., 61, 277-283.
6. Hsu, J.C., Metcalf, R.A., Sun, T., Welsh, J.A., Wang, N.J. and Harris, C.C. (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature, 350, 427-428.
7. V8hdkangas, K.H., Samet, J.M., Metcalf, R.A., Welsh, J.A., Bennett, W.P., Lane, D.P. and Harris, C.C. (1992) Mutations ofp53 and ras genes in radon-associated lung cancer from uranium miners. Lancet, 339, 576-580.
8. Brash, D.E., Rudolph, J.A., Simon, J.A., Lin, A., McKenna, GJ., Baden, H.P., Halperin, A.J. and Pontdn, J. (1991) A role for sunlight in slrin cancer UV-induced p53 mutations in squamous cell carcinoma. Proc. NatL Acad. Sci. USA, 88, 10124-10128.
9. Mostofi, F.K., Sobin, L.H. and Torloni, H. (1973) Histological typing of urinary bladder tumours. WHO International Histological Classification of Honours, no. 10. World Health Organization, Geneva.
10. Wright, D.K. and Manos, M. (1990) Sample preparation from paraffin-embedded tissues. In Innis, M.A., Gdfand, D.H., Sninsky JJ. and Write, T.J. (eds), PCR Protocols. Academic Press, San Diego, CA, pp. 153-158.
11. Sambrook, J., Fritscb, E.F. and Maniatis, T. (1989) In Nolan, C. (ed.), Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp 13.1-13.104.
12. Orita, M., Suzuki, Y., Selriya, T. and Hayashi, K. (1989) Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 5, 874-879.
13. Buchman, V.L., Chumakov, P.M., Ninkina, N.N., Samarina, O.P. and GeoTgiev, G.P. (1988) A variation in the structure of the protein-coding region of the human p53 gene. Gene, 70, 245-252.
14. Gaidano, G., Ballerini, P., Gong, J.Z., Inghiram, G., Newcomb, E.W., Magrath, I.T., Knowles, D.M. and Dalla-Favera, R. (1991) p53 mutations in human lymphoid malignancies: association with Buridtt's lymphoma and chronic lymphocytic leukemia. Proc. NatL Acad. Sci. USA, 88, 5413-5417.
15. Ohgaki, H., Eflri, R.H., Wiesder, O.D., Yasargil, M.G., Newcomb, E.W. and Kleihues, P. (1991) p53 Mutations in non-astrocytic htnnan brain tumors. Cancer Res., 51, 6202-6205.
16. Ohgald, H., Kleihues, P. and Heitz, P.U. (1993) p53 mutations in sporadic adrenocortical tumors, lnt. J. Cancer, 54, 408-410.
17. Isaka, H., Yoshii, H., Otsuji, A., Koike, M., Nagai, Y., Koura, M., Sugiyasu, K. and Kanabayashi, T. (1979) Tumors of Sprague-Dawley rats induced by longterm feeding of phenacetin. Gann, 70, 29-36.
18. Johansson, S.L. (1981) Carcinogenicity of analgesics: long term treatment of Sprague-Dawley rats with phenacetin, phenazone, caffeine and paracetamol (acetaminophen), lnt. J. Cancer, 27, 521-529.
19. Nakanishi, K., Kurata, Y., Oshima, M., Fukushima, S. and Ito, N. (1982) Carcinogenicity of phenacetin: long-term feeding study in B6C3F] mice. Int. J. Cancer, 29, 439-444.
20. Camus, A.-M., Friesen, M., Croisy, A. and Bartsch, H. (1982) Species-specific activation of phenacetin into bacterial mutagens by hamster liver enzymes and identification of N-hydroxyphenacetin O-glucuronide as a promutagen in the urine. Cancer Res., 42, 3201-3208.
21. De Flora, S., Russo, P., Pala, M., Fassina, G., Zunino, A., Bennicelli, C., Zanacchi, P., Camoirano, A. and Parodi, S. (1985) Assay of phenacetin genotoxicity using in vitro and in vivo test systems. J. TaxicoL Enwron. Health, 16, 355-377.
22. Oldhamr, I.W., Preston, R.F. and Paulson J.D. (1986) Mutagenicity testing of selected analgesics in Ames Salmonella strains. J. AppL TaxicoL, 6, 237-243.
23. Mulder, G. J., Kadlubar, F. F., Mays, J. B. and Hinson, J.A. (1984) Reaction of mutagenic phenacetin metabolites with glutathione and DNA. MoL PharmacoL, 26, 342-347.
24. AnderstrfSm, C., Johansson, S.L. and von Schultz, L. (1983) The influence of phenacetin or mechanical perforation on the development of renal pelvic and urinary bladder tumors in FAN FT-induced urinary tract carcinogenesis. Acta PathoL MicrobioL Immunol. Scand. A, 91, 373-380.
25. Nakanishi, K., Fukushima, S., Shibata, M., Shirai, T., Ogiso, T. and Ito, N. (1978) Effect of phenacetin and caffeine on the urinary bladder of rats treated with N-butyl-A'-(4-hydroxybutyl)mtrosamine. Gann, 69, 395-400.
26. Johansson, S.L., Radio, S.J., Saidi, J. and Sakata, T. (1989) Tbc effects of acetaminophen, antipyrine and phenacetin on rat urothelial cell proliferation. Carcinogenesis, 10, 105-111.
27. Kunze, E., Wöltjen, H.H. and Albrecht, H. (1983) Absence of a complete carcinogenic effect of phenacetin on the quiescent and protiferating urothdium stimulated by partial cystectomy. UroL Int., 38, 95-103.
28. Ludeke, B.I., Ohgaki, H. and Kleihues, P. (1993) Generic Titmor Epidemiology: Identifying Causative Carcinogenic Agents and their Transforming Mutations. American Chemical Society, Washington, DC, in press.
29. Coulondre, C., MiTler, J.H., Farabaugh, P.J. and Gilbert, W. (1978) Molecular basis of base substitution hotspots in Escherichia co, U. Nature, 274, 775-780.
30. Nguyen, T., Bnmson, D., Crespi, C.L., Penman, B.W., Wishnok, J.S. and Tannenbaum, S. R. (1992) DNA damage and1 mutation in human cells exposed to nitric oxide in vitro. Proc. NatL Acad. Sei. USA, 89, 3030-3034.
31. Badawi, A.F., Mostafa, M.H. and O’Connor, P.J. (1992) Involvement of alkylating agents in schistosome-associated bladder cancer: the possible basic nwhnnjgnu of induction. Cancer Lett., 63, 171-188.
32. Sidransky, D., von Eschenbach, A., Tsai, Y.C., Jones, P., Summerhayes, I., Marshall, F., Paul, M., Green, P., Hamilton, S.R., Frost, P. and Vogelstein, B. (1991) Identification of p53 gene mutations in bladder cancers and urine samples. Science, 252, 706-709.
33. Fujimoto, K., Yamada, Y., Okajima, E., Kalrizoe, T., Sasaki, H., Sugimura, T. and Terada, M. (1992) Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res., 52, 1393-1398.
34. Spruck, C.H., Rideout, W.M., Olumi A F., Ohneseic, P.F., Yang A S., Tsai, Y.C., Nichols, P.W., Hom, T., Hermann, G.G., Steven, K., Ross, R.K., Yu, M.C. and Jones, P.A. (1993) Distinct pattem of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Res., 53, 1162-1166.
35. Fujita, J., Yoshida, O., Yuasa, Y., Rhim, J.S., Hatanaka, M. and Aaronsoo, S.A. (1984) Ha-ras oncogenes are activated by somatic alterations in human urinaty tract tumours. Nature, 300, 464-466.
36. Fujita, J., Srivastava, S.K., Kraus, M.H., Rhim, J.S., Tronick, S.R. and Aaronson, S.A. (1985) Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumors. Proc. NatL Acad. Sei. USA, 82, 3849-3853.
37. Malone, P.R., Visvanathan, K.V., Ponder, B.A.J., Shearer, R.J. and Summerhayes, I.C. (1985) Oncogenes and bladder cancer. Br. J. UroL, 57, 664-667.
38. Visvanathan, K.V., Pocock, R.D. and Summerhayes, I.C. (1988) Preferential and novel activation of H-nsu in human bladder carcinomas. Oncogene Res., 3, 77-86.
39. Meyers, F.J., Gumeriock, P.H., Kokoris, S.P., DeVere White, R.W. and McConnick, F. (1989) Human bladder and colon carcinomas contain activated ras p21. Cancer, 63, 2177-2181.
40. Nagata, Y., Abe, M., Kobayashi, K., Saiki, S., Kotake, T., Yoshikawa, K., Ueda, R., Nakayama, E. and Shiku, H. (1990) Point mutations of c-ras genes in human bladder cancer and kidney cancer. Jpn. J. Cancer Res., 81, 22-27.
41. Rochlitz, C.F., Peter, S., Willroth, G., de Kant, E., Lobeck, H., Huhn, D. and Herrmann, R. (1992) Mutations in the rot protooncogenes are rare events in renal cell cancer. Eur. J. Cancer, 28, 333-336.
42. Knowles, M.A. and Williamson, M. (1993) Mutation of H-rar is infrequent in bladder cancer confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and dimet sequencing. Cancer Res., 53, 133-139.
43. Sameshima, Y., Matsuno, Y., Hirohashi, S., Shimosato, Y., Mizoguchi, H., Sugimura, T., Terada, M. and Yokota, J. (1992) Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene, 7, 451-457.
44. Bennett, W.P., Hollstein, M.C., Metcalf, R.A., Welsh, J.A., He, A., Zhu, S., Kusters, J., Resau, J.H., Trump, B.F., Iane, D P. and Harris, C.C. (1992) p53 mutations and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res., 52, 6092-6097.